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1. Introduction  
Human alpha-1-proteinase inhibitor (1-PI) is a well-characterized multifunctional protease 
inhibitor, the major physiological role of which is inhibition of neutrophil elastase (NE) in 
the lungs. The importance of1-PI is underlined by its deficiency which is characterized by 
low levels of 1-PI in the circulation. Under such conditions, lower levels of 1-PI are 
transported to tissues, including the fragile alveoli of the lungs. 1-PI deficiency (with levels 
of 1-PI in blood below 11 M, insufficient for inhibition of proteolytic enzymes in the 
lungs) is a common genetic condition predisposing 1-PI-deficient individuals to the 
development of chronic obstructive pulmonary disease (COPD). Hereditary1-PI deficiency 
is classically associated with the development of premature, ultimately fatal, panacinar 
emphysema. To slow down the progression of emphysema, several licensed 1-PI 
concentrate preparations derived from pooled human plasma are currently available for 
intravenous augmentation therapy for patients with congenital 1-PI deficiency and 
clinically evident emphysema. In addition, and as an alternative to the plasma-derived 1-PI 
products, multiple efforts have been made to develop recombinant versions of human 1-PI 
over the last three decades. This review describes the recent advances in the research and 
development of human 1-PI for therapetic use and covers the following: characterization of 
human 1-PI; epidemiology of 1-PI deficiency and currently licensed treatment; summary 
of the manufacturing and recent quality improvements of the 1-PI plasma-derived 
products; safety and efficacy of 1-PI intravenous augmentation and alternative routes; 
development of recombinant versions of human 1-PI; conditions other than emphysema 
that are associated with 1-PI; and some other aspects related to the research and 
development of 1-PI for therapeutic use.  
                                                 
 The findings and conclusions in this article have not been  formally disseminated by the Food  
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2. Human 1-PI and 1-PI deficiency  
2.1 Structure and function of 1-PI  
Human alpha-1-proteinase inhibitor (ǂ1−PI), also known as alpha-1-antitrypsin, is the most 
abundant inhibitor of serine proteases in plasma. It is predominantly synthesized in 
hepatocytes, but is also produced, to a lower extent, by alveolar macrophages, neutrophils, 
and some other cells (White et al., 1981; Carlson et al., 1988; Paakko et al., 1996). In healthy 
individuals, the concentration of ǂ1−PI in blood normally varies from 20 µM to 53 µM (1.04-
2.76 g/L) (Brantly et al., 1988; Brantly et al., 1991) with a half-life in the circulation of about 
3-5 days (Crystal, 1989; Kalsheker et al., 2002). Though ǂ1−PI has a wide range of inhibitory 
activities, its main physiological role is known to be the inhibition of polymorphonuclear 
leukocyte (neutrophil) elastase (NE) in the lungs (Travis, 1988). In the lower respiratory tract 
of healthy lungs, 1–PI provides more than 90% of the anti–neutrophil elastase protection 
(Crystal, 1991; Crystal et al., 1989). Hereditary ǂ1−PI deficiency (with levels of ǂ1−PI in 
blood below 11 µM, insufficient for inhibition of NE) is classically associated with 
development of early-onset pulmonary emphysema, a hallmark of ǂ1−PI deficiency (Crystal 
et al., 1989; Snider, 1992). Smoking is known to be the biggest risk factor for developing 
emphysema; in smokers with ǂ1−PI deficiency a severe lung impairment is usually observed 
in their fourth decade of life. 
ǂ1-PI is encoded by a single 12.2 kb gene (Pi) located on the long arm of chromosome 14 
(Long et al., 1984; Rabin et al., 1986). Over 120 alleles of ǂ1−PI have been identified with 
approximately 35 of them being associated with ǂ1−PI deficiency, including Z-allele, which 
is the most common cause of the deficiency when inherited in a homozygous fashion. Due 
to a single mutation in the mobile domain (Glu342Lys), the ǂ1−PI Z-mutant undergoes 
aberrant conformational transitions that prompts the protein to aggregate. This results in 
retention of polymerized ǂ1−PI Z mutant within hepatocytes, thus inducing disease 
conditions in the liver and causing ǂ1−PI deficiency in the circulation (Ekeowa et al., 2011; 
Lomas, 2005; Volpert et al., 2000). The prevalence of three major ǂ1−PI variants (PiM, PiS, 
and PiZ) defines the number of carriers (PiMZ and PiMS) and individuals with deficiency 
phenotypes ( PiZZ, PiSZ, and PiSS). The epidemiology of ǂ1−PI deficiency and its clinical 
manifestations, including lung diseases and liver diseases, has been described in detail 
(Ekeowa et al., 2011; Luisetti & Seersholm, 2004; Needham & Stockley, 2004; Gooptu & 
Lomas, 2009). Based on the ǂ1−PI serum concentration, a common classification to define 
ǂ1−PI deficiency includes the four major categories: (1) normal (with ǂ1−PI serum levels not 
lower than 20 M); (2) deficient (with ǂ1−PI concentrations in serum lower than 20 M); (3) 
dysfunctional (with normal ǂ1−PI level, but lost or lower inhibitory activity); and (4) null 
(with ǂ1−PI serum concentrations below the detectable level). 
ǂ1−PI is a 52 kDa glycoprotein belonging to the serine protease inhibitor (serpin) 
superfamily, which in addition to ǂ1-PI also includes 1-antichymotrypsin, antithrombin, 
plasminogen activator inhibitor, C1 esterase inhibitor, and many others (Stein & Carrell, 
1995; Silverman et al., 2001). A single polypeptide chain of  ǂ1-PI is comprised of 394 amino 
acid residues, including one cysteine, 2 tryptophanes, and 9 methionine residues (Carp et 
al., 1982; Johnson & Travis, 1979). Three N-linked glycans attached to asparagine residues 
46, 83, and 247 represent ~12% of ǂ1−PI by molecular weight (Mega et al., 1980a,b;  
Carrell et al., 1981, 1982). The carbohydrate moiety is comprised of biantennary N-glycans, 
but also triantennary and traces of tetraantennary structures grounded on the mannose fork 
core and containing N-acetyl glucosamine, galactose, and terminal negatively-charged sialic 
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(N-acetylneuraminic) acid (Mega et al., 1980b; Travis & Salvesen, 1983; Kolarich et al., 
2006a). The glycosylation pattern is a major cause of the iso-electric focusing (IEF) pattern 
typical for ǂ1−PI with major isoforms M2, M4, M6, and also M7 and M8 due to the N-
terminal truncation (Jeppsson et al., 1985; Kolarich et al., 2006a,b). Some characteristics of 
human ǂ1−PI are listed in Table 1. Like the majority of other native glycoproteins, ǂ1-PI is 
intrinsically a highly heterogeneous moiety, mainly due to variably trimmed glycosylation 
and an N-terminal pentapeptide that can be absent (Hercz, 1985; Krasnewich et al., 1995; 
Vaughan et al., 1982). 
 
Characteristics Description 
Synonyms  alpha-1-proteinase inhibitor, alpha-1-antitrypsin 
Common abbreviations ǂ1−PI, alpha-1-PI, ǂ1−AT, alpha-1-AT, A1AT, ATT, AT 
Classification Serine proteinase inhibitor (serpin) 
Substrates Neutrophil elastase, trypsin, chymotrypsin 
Molecular weight 52,000 Da (50,300 Da by mass spectrometric analysis) 
Glycosylation Three N-attached carbohydrates (12% w/w) 
Polypeptide Single polypeptide chain of 394 amino acid residues 
Heterogeneity Highly heterogeneous protein 
Major isoforms M2, M4, M6, M7 and M8 
Half-life in circulation 3-5 days (for native plasma ǂ1−PI) 
Concentration in blood Acute-phase plasma protein, concentration normally 
varies from 20 µM to 53 µM (1.04-2.76 g/L) 
Major biological activities Inhibitory anti-serine proteinase activity 
Multiple non-inhibitory activities 
Aggregation ǂ1−PI Z mutant is naturally prone to aggregation 
ǂ1−PI S mutant aggregates to a lower degree 
Physiologically important 
phenotypes 
PiMM (normal); PiSS, PiSZ & PiZZ (deficiency 
phenotypes); PiZZ, PiSS & PiNull (the most abnormal) 
Diagnostic ǂ1-PI variants 
(serum concentrations) 
Normal (NLTa 20 M); Deficient (lower than 20 M; 
Dysfunctional (NLT 20 M, inactive); Null (n.d.b level) 
Diseases related to ǂ1−PI 
deficiency and aggregation 
Pulmonary and liver diseases 
Other rare diseases (putative)c 
a NLT, not lower than; b n.d., non-detectable; c See Table 3 
Table 1. Characteristics of human ǂ1-PI 
Figure 1 shows a crystal structure of ǂ1-PI, typical for serpins, which features 9 ǂ-helices, 3 
ǃ-sheets (A, B, and C), and a mobile 15-residue reactive center loop (RCL) exposed for 
interaction with the target serine protease (Johnson & Travis, 1979; Lomas, 2005).  Protease 
attack of the RCL results in cleavage at Met358-Ser359, formation of a covalent ǂ1-PI-
protease complex with the amino-terminal polypeptide inserted into the A ǃ-sheet, and an 
overall dramatic conformational change (Huntington et al., 2000; Ludeman et al., 2001; 
Stratikos & Gettins, 1999; Wilczynska et al., 1997).  
Unlike the majority of proteins, ǂ1−PI is naturally folded in a metastable structure which is 
essential for its function. This is not the most thermodynamically stable form, and thus, ǂ1-
PI is prone to a variety of conformational transitions and modifications (Lomas, 2005; Lomas 
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Lung Diseases – Selected State of the Art Reviews 
 
86
et al., 1995). Much like other serpins, ǂ1-PI can intramolecularly convert into a more stable 
latent form, which is inactive, but the biological activity can be restored via denaturation 
and refolding (Lomas et al., 1995; Silverman et al., 2001).   
 
 
Fig. 1. Crystal structure of ǂ1-PI (PDB 1HP7) in two projections. (A) Front view at the ǂ1-PI    
structure in respect to -sheet A, and (B) Side view obtained by 90o clockwise rotation of the 
molecule. The images were obtained using PyMOL (the PyMOL Molecular Graphics 
System, Version 1.1r1, Schrödinger, LLC). 
In addition to its inhibitory antiprotease function, ǂ1−PI exhibits a broad spectrum of non-
inhibitory activities (Brantly, 2002; Janciauskiene et al., 2011; Nita et al., 2005). Because of  
the nine methionine residues in ǂ1−PI molecule, its plausible role as a putative antioxidant 
has been suggested (e.g., Levine et al., 1999, 2000).  
Due to the abundance of ǂ1−PI in human plasma and its conservative tertiary structure with 
hydrophobic cavities (Elliott et al., 2000; Lee et al., 2001; Parfrey et al., 2003), ǂ1−PI has the 
capacity to bind small hydrophobic molecules. This property has been explored mainly with 
respect to the peptides and small molecules that may prevent the aggregation of the ǂ1−PI Z 
mutant (Mahadeva et al. 2002; Mallya et al., 2007; Chang et al. 2009).  
2.2 The 1-PI deficiency and 1-PI replacement therapy 
There are approximately 60,000-100,000 severely deficient individuals in the United States 
which define ǂ1-PI deficiency as a rare disease. However, according to several publications, 
ǂ1-PI deficiency is widely under- and mis-diagnosed (e.g., de Serres, 2003; Bals et al., 2007). 
As reported by the World Health Organization (WHO, 1997), only 4% of  the individuals 
with ǂ1-PI deficiency cases are identified, and only a portion of them are receiving 
treatment. Currently licensed treatment of the patients with ǂ1-PI deficiency and 
manifestation of pulmonary emphysema involves intravenous infusion of plasma-derived 
ǂ1-PI preparations with the recommended dose of 60 mg of active ǂ1-PI per kg of body 
weight administered once weekly. To maintain a threshold level of ǂ1-PI (11µM), ǂ1−PI- 
deficient patients should receive augmentation therapy for the duration of their lives, to 
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levels observed in the plasma of individuals who are heterozygous for Z-mutant ǂ1−PI and 
who do not develop emphysema. Evaluation of the efficacy of ǂ1-PI products used in clinical 
studies is based on surrogate markers: the infusion of ǂ1-PI must elevate the circulating 
serum level of ǂ1−PI above an epidemiologically established ‘protective threshold’ and the 
protein must be detectable in bronchoalveolar lavage fluid (Juvelekian & Stoller, 2004; 
Sandhaus, 2009). However, the ability of ǂ1-PI augmentation therapy to reduce the 
progression of emphysema still remains to be proven. Safety and efficacy of intravenous ǂ1-
PI augmentation are considered in section 3.3.1. For other disease conditions that may 
possibly benefit from ǂ1-PI therapy see section 3.3.3.  
3. Research and development of 1-PI for therapeutic use 
3.1 Plasma-derived 1-PI products  
3.1.1 Currently approved 1-PI products  
Currently there are six commercial plasma-derived ǂ1-PI products (Table 2) licensed by the 
US FDA for intravenous treatment of patients with hereditary ǂ1-PI deficiency who show 
evidence of emphysema. Prolastin® (registered trade name of Bayer Corporation since 1987) 
was the first ǂ1-PI product to be approved. Since 2005, when Bayer Corporation was 
acquired by Talecris Biotherapeutics (Research Triangle Park, NC, USA; www.talecris.com), 
the product has been manufactured by Talecris. Aralast® (initially registered trademark of 
Alpha Therapeutic Corporation) was approved in 2003, and has been manufactured under 
the direction of Baxter Healthcare Corporation since then (Baxter, Westlake Village, CA, USA 
www.baxter.com). Zemaira® (registered trade name of Aventis Behring since 2003), another 
available product, is now manufactured by CSL Behring LLC (Kankakee, IL, USA; 
www.cslbehring-us.com). In 2007, the US FDA approved another of Baxter’s preparations of 
ǂ1-PI concentrate - Aralast NP® - that has the same formulation as its predecessor, but differs 
from the earlier approved product by having a significantly lower content of C-terminal 
lysine-truncated ǂ1-PI (approximately 2% vs. 67%). In 2009, the US FDA approved Prolastin 
C®, the updated version  of the earlier Talecris product that had been on the market for more 
than two decades. Due to more sophisticated purification and pathogen reduction steps, 
including  two dedicated viral inactivation steps instead of heat treatment, the specific activity 
of Prolastin C® (above 0.7 mg of functional ǂ1-PI per mg of total protein) is twice higher than 
that of Prolastin®, which means that lower volumes and shorter transfusion time are needed. 
Most recently, in July 2010, the FDA approved GlassiaTM (formerly Respira), a product 
manufactured by Kamada (Weizmann Science Park, Ness Ziona, Israel; www.kamada.com) 
and commercially launched by Baxter in the United States and some other countries. GlassiaTM 
is another highly purified ǂ1-PI (with specific activity above 0.7 mg of active ǂ1-PI per mg of 
total protein) and the only ǂ1-PI product that is available in a ready-to-use liquid form with a 
shelf-life stability of two years under refrigerated conditions.  
ǂ1−PI products are manufactured as part of a complex plasma fractionation scheme which 
was originally developed for large-scale production of albumin, but now also yields many 
other plasma therapeutics. Since products are made from pooled human plasma, they may   
                                                 










Date of  
licensure Product form 




12/2/1987 Lyophilized  
powderb 
Depth Filtration Heat 
Treatment 
Aralast®c Baxter 
Healthcare Co.  




Zemaira® CSL Behring 7/8/2003 
Lyophilized  
powder 
Heat Treatment  & 
Ultrafiltration 










 GlassiaTM Kamada 7/1/2010 Ready-to-use liquid 
Solvent/Detergent & 
Nanofiltration 
a Based on recent publications including (Stockley, 2010; Tonelli & Brantly, 2010)  
b Reconstitution using Sterile Water for Injection is required  
c  Aralast®, previously known as Respitin, contains approximately 67% of ǂ1-PI with the truncated  
C-terminal lysine (Lys394)  
d Aralast NP® contains approximately 2% of ǂ1-PI with truncation of C-terminal lysine residue 
Table 2. The plasma-derived ǂ1-PI therapeutic products approved by the US FDA for   
chronic augmentation and maintenance therapy in adults with congenital ǂ1-PI deficiency 
and clinically evident emphysemaa 
carry the risk of transmitting human infectious agents, e.g., some viruses, and theoretically, 
the Creutzfeldt-Jakob disease (CJD) agent or disease variant agents, as well as emerging or 
unknown infectious agents. To reduce the potential risk of transmitting infectious agents, 
the ǂ1-PI preparations are manufactured using a number of viral inactivation and removal 
steps. Currently approved ǂ1−PI products differ in the procedures used for pathogen 
reduction. For instance, the heat treatment procedure used in manufacturing of Prolastin 
was one of the reasons for higher content of inactive and aggregated ǂ1−PI in the product. 
The manufacturing procedures of the later products (Table 2) include two dedicated steps 
that are specifically designed for inactivation and removal of viruses (Hotta et al., 2010). 
Thus, solvent/detergent treatment and nanofiltration are used as the dedicated pathogen 
reduction steps in the manufacturing of recently approved Prolastin C®, GlassiaTM  and both 
Aralast products. Overall, the manufacturing history of plasma-derived ǂ1-PI therapeutic 
products reflects a trend of continous improvement of product quality.  
3.1.2 Heterogeneity of α1-PI products  
Heterogeneity of ǂ1-PI therapeutic preparations is a complex phenomenon. First of all,  
heterogeneous nature of plasma ǂ1-PI is an intrinsic property of the native glycoproten (see 
2.1). Second, the presence of variously processed ǂ1-PI forms including latent, cleaved, 
complexed or aggregated ǂ1-PI species, is barely avoidable. However, it must be kept 
minimal as the inactive protein species have a direct influence on the product’s specific 
activity. Third, ǂ1-PI products purified from pooled human plasma contain certain 
impurities of other plasma proteins, including albumin, haptoglobin, ǂ1-antichymotrypsin, 
ǂ1-lipoprotein, antithrombin III, C1-esterase inhibitor, etc. The human origin of these 
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impurities ensures their tolerability, however, the level of these plasma proteins in ǂ1-PI 
concentrate may significantly increase the non-therapeutic protein load in the ǂ1-PI 
preparation intended for transfusion. In addition to all that, multistep manufacturing 
procedures are known to induce various protein alterations, such as aggregation and 
chemical modifications (e.g., deamidation, cysteinylation, and C-terminal truncation). Some 
modifications can be observed by IEF and other techniques (Cowden et al., 2005; Kolarich et 
al., 2006a, 2006b) and reflected in the product specifications. Currently there are no data that 
would demonstrate whether these alterations affect the in vivo activity, safety, efficacy or 
immunogenicity of ǂ1-PI therapeutic preparations. In general, commercial plasma-derived 
ǂ1-PI products differ in terms of their purity, specific activity, modifications, and excipients 
(Lomas et al., 1997; Cowden et al., 2005; Stockley, 2010; Tonelli & Brantly, 2010).    
3.2 Research and development of the recombinant versions of human 1-PI  
3.2.1 Advances in the development of recombinant α1-PI  
The plasma supply per se is a limited source and appears to be insufficient to meet 
anticipated clinical demand. Moreover, despite effective viral inactivation/removal  steps in 
the manufacturing of plasma proteins (Cai et al., 2005; Hotta et al., 2010), the risk of 
contamination with new and unknown pathogens may still exist. Therefore, recombinant 
technology has been widely explored as an alternative approach for the production of 
human ǂ1-PI since the pioneering works of the early 1980s (Bollen et al., 1983; Cabezon et al., 
1984; Rosenberg et al., 1984). As evident from numerous reports, both from academic 
research and industry, the human gene for ǂ1-PI has been expressed in virtually all available 
hosts (E. coli, various yeasts, fungi, insect cells, CHO cells, human neuronal cells, and 
produced in transgenic plants and animals). For more details on  research and development 
of recombinant ǂ1-PI (r-ǂ1-PI) in different systems and advances and limitations of the 
recombinant approach for production of stable and biologically active ǂ1-PI, see our 
comprehensive 2006 review (Karnaukhova et al., 2006). More recently, the human gene for 
ǂ1-PI has been expressed in filamentous fungi (Chill et al., 2009; Karnaukhova et al., 2007), 
transgenic tomato plants (Agarwal et al., 2009), tobacco cell cultures (Huang et al., 2009; 
Nadai et al., 2009), and human neuronal cell lines (Blanchard et al., 2011). Nevertheless, no r-
ǂ1-PI  is available as a licensed therapeutic treatment. In general, the essential criteria for the 
development of therapeutics for human use are safety, optimal clinical efficacy, and 
maximum cost-effectiveness. Among many efforts to develop r-ǂ1-PI of therapeutic quality 
(see Karnaukhova et al., 2006), there appear to be only two examples of the r-ǂ1-PIs for 
which development went far enough to get to clinical trials. The first was r-ǂ1-PI produced 
in the yeasts Saccromyces cerevisiae and manufactured by Arriva Pharmaceuticals Inc. 
(Arriva) for several indications. A nebulized formulation of  this non-glycosylated r-ǂ1-PI 
preparation has been intended for the treatment of respiratory disorders including 
emphysema and COPD (phase II clinical trials), and asthma (pre-clinical studies) (Brown, 
2006a). Although animal studies have been considered  to be successful (Pemberton et al., 
2006), human trials have not been recommended (see review by Stokley, 2010). A topical gel 
formulation of r-ǂ1-PI has been intended for the treatment of dermatitis and other severe 
dermatological disorders in phase II clinical trials (see Brown, 2006b).  
The second example of the advanced development of recombinant human ǂ1-PI is large 
scale production performed in transgenic dairy animals (t-ǂ1-PI): sheep [by PPL 
Therapeutics (UK) in partnership with Bayer Biologicals (USA), (Dalrymple & Garner, 1998;  
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Wright et al., 1991)], and goats [by Genzyme Transgenics Corporation (USA), (Ziomek, 
1998)]. The transgenic ǂ1-PI  recovered from sheep milk was purified to 99.9% purity.  Even 
so, sheep native ǂ1-PI and sheep ǂ1-antichymotrypsin were major impurities, at 6.7-18.7 
mg/L and 60.3-75.8 parts per million, respectively. Two sequential clinical studies were 
performed to evaluate the safety and immunogenicity of aerosolized transgenic human ǂ1-
PI. None of the subjects had an antibody response to human t-ǂ1-PI (Tebbutt, 2000; Spencer 
et al., 2005); however, antibody responses were observed to sheep ǂ1-PI and to sheep ǂ1-
antichymotrypsin (Spencer et al., 2005).  Four patients withdrew from the study due to the 
development of dyspnea and a decline in lung function, and the later product development 
was terminated.   
3.2.2 Pitfalls in the development of r-α1-PI for therapeutic use  
The general regulatory requirements for biologicals intended for therapeutic use, including 
r-ǂ1-PI, are purity, safety, and efficacy. In order to be effective, therapeutic proteins have to 
be stable in vivo and in vitro (Karnaukhova et al., 2006). Reviewing the work performed over 
the last two decades to produce stable and biologically active r-ǂ1-PI of therapeutic quality, 
one can see basically two major factors that were impeding the progress: (1) impurities that 
could induce antibody responses and cause adverse reactions in patients, and (2) lower 
stability than that of plasma counterpart, mainly caused by the lack of glycosylation or non-
human type of glycosylation (the latter may also induce immune responses). Although 
presently the first reason can be technically better solved, removal of trace amounts of non-
human native proteins derived from the host, e.g., sheep ǂ1-PI, from the human r-ǂ1-PI to 
exclude further adverse reactions, requires a much higher level of purification than was 
possible at the time of that development. As for the second reason, indeed, glycosylation is 
considered to be a cause of rapid clearance of r-ǂ1-PI from the circulation (Casolaro et al., 
1987; Cantin et al., 2002a). Aberrant glycosylation (or lack of glycans) does not neccessarily 
affect biological activity of the recombinant protein, but it is important for its stability. 
According to recently published data, glycosylation of ǂ1-PI does not interfere with the 
serpin native state flexibility (or instability) essential for its efficient function, though it may 
confer resistance to degradation by proteases and thus extend its half-life in the circulation 
(Sarkar & Wintrode,  2011). Extensive work performed over decades for the development of 
viable r-ǂ1-PI of therapeutic quality and lessons learned from these experiences truly paved 
the way for other protein therapeutics. It is worthwhile to mention two serpins produced in  
transgenic animals that were recently approved. In 2009, the US FDA approved recombinant 
antithrombin (ATryn®) produced in the milk of transgenic goats (Fyfe & Tait, 2009). In 2010, 
another serpin, recombinant human C1-esterase inhibitor (Ruconest®) produced in the milk 
of transgenic rabbits was granted European marketing authorization (Varga & Farkas, 2011). 
Both pharmaceutical proteins show a faster clearance, yet it may not be an issue depending 
on the intended use. For instance, Ruconest® was approved for the treatment of acute 
attacks of hereditary angioedema, and therefore there is no need to maintain its higher level 
in blood longer than its action is required. Given a shorter in vivo half-life of recombinant ǂ1-
PI, it has been considered for other administration routes and applications, such as 
inhalation for the treatment of emphysematous condition, and topical application for 
various skin diseases. However, a convincing proof of the recombinant product efficacy and 
safety in appropriate clinical trials is as problematic as it is for plasma-derived ǂ1-PI; large 
clinical trials in the cases of rare diseases are difficult to perform because of small 
geographically dispersed patient populations. In addition, a limited population means a 
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limited market, which is less attractive for large investments. No doubt, these reasons 
markedly slow down the development of r-ǂ1-PI. 
3.31-PI –based therapies 
3.3.1 Safety and efficacy of intravenous 1-PI augmentation  
The intravenous augmentation of ǂ1-PI was shown to be safe and well tolerated over a long 
history of the replacement therapy. However, its impact on disease progression and 
mortality still remains to be convincingly proven. ǂ1-PI augmentation is assumed to slow 
down the rate of emphysema development and progression and, thus, to improve the life 
quality and duration of ǂ1-PI deficient patients, yet the essential proof of efficacy is missing. 
According to Hubbard & Crystal (1990), only approximately 2-3% of infused ǂ1−PI actually 
reaches the lungs; and the effictiveness of ǂ1-PI replacement therapy has been evaluated 
mainly on the bases of biochemical (not clinical) criteria (Tonelli & Brantly, 2010). For 
recently approved ǂ1-PI products, their pharmacokinetic equivalence and comparable safety 
profile to Prolastin were demonstrated (e.g., Stocks et al., 2010). ǂ1-PI  therapy is a life-long 
and very expensive treatment that may cost up to $150,000 (Silverman, 2009) in the United 
States. Whether this therapy decreases mortality also remains unknown, as there are no 
reliable data on mortality, as well as morbidity and survival (Gøtzsche & Johansen, 2010a). 
Some observational studies support the idea that augmentation therapy may help to slow 
the decline in lung function (Seersholm et al., 1997; Wencker et al., 2001; Kueppers, 2011). 
But there are also more critical evaluations including the opinion that ǂ1-PI augmentation 
therapy cannot be recommended due to lack of evidence of clinical benefit and the cost of 
treatment (Gøtzsche & Johansen, 2010a, 2010b). It is currently widely admitted that the 
efficacy of ǂ1-PI augmentation therapy has never been persuasively demonstrated and must 
be proven in a proper clinical trial. Due to the widespread and small clusters of patients all 
over the country, conducting a prospective, randomized, placebo-controlled clinical trial is 
challenging. In addition, the development of emphysema proceeds slowly, creating the 
additional difficulties of monitoring lung function decline and mortality data (Hutchinson & 
Hughes, 1997; Schluchter et al., 2000).   
3.3.2 Alternative routes of administration of 1-PI products 
Due to the inconvenience of life-time intravenous augmentation therapy and low levels of 
ǂ1−PI reaching lungs, the inhalation of aerosolized ǂ1-PI has been suggested as a less 
invasive and more efficient way to deliver large amounts of ǂ1-PI directly to the lungs where 
it is most needed (Hubbard et al., 1989; McElvaney et al., 1991; Cockett, 1999). Although 
strategies for aerosol therapy of ǂ1-PI deficiency has been proposed two decades ago 
(Hubbard et al., 1989; Hubbard & Crystal, 1990), there is still no ǂ1-PI aerosolized treatment 
approved. Several studies examined efficiency of the ǂ1-PI inhalation therapy in animals 
and in humans (Kropp et al., 2001; Siekmeier, 2010). It was demonstrated (Kropp et al., 2001) 
that significantly more ǂ1-PI was deposited in the lungs through the inhalational route than 
via intravenous infusion (14.6% vs. 2%). Although the inhalation route seems attractive, 
nevertheless, enabling the inhaled material to reach the lung interstitium, the most 
important to the emphysematous process region, is still problematic. With regards to 
recombinant versions of ǂ1-PI, it is generally assumed that products directly delivered to the 
lungs may not require the same degree of stability as ǂ1-PI given intravenously. However, 
as mentioned above, human studies using r-ǂ1-PI from transgenic sheep were associated 
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with adverse reactions due to impurities derived from the host (Spenser et al., 2005). Thus, 
higher levels of purification and more clinical studies are required.  
3.3.3 Other 1-PI applications 
Currently, ǂ1-PI therapeutic preparations are licensed exclusively for one indication, i.e., 
chronic augmentation and maintenance therapy in individuals with emphysema due to 
congenital ǂ1-PI deficiency. Previously unrecognized inherited disorder, ǂ1-PI deficiency 
was first described in 1963 (Laurell & Eriksson, 1963) based on the serum electrophoretic 
analysis that revealed five individuals deficient of ǂ1–fraction; three of those patients had 
developed emphysematous conditions. Six years later, in 1969, cirrosis associated with ǂ1-PI 
deficiency was described (Sharp et al., 1969). These findings initiated a concept of linkage 
between ǂ1-PI deficiency and pulmonary and liver diseases. As evident from the available 
literature, due to the multiple biological activities of ǂ1-PI, it has been associated with other 
lung diseases (first of all, cystic fibrosis) and many non-pulmonary diseases (Table 3).  Some 
of these conditions may possibly benefit from ǂ1-PI augmentation therapy (see recent 
reviewes by Blanco et al., 2011 and Janciauskiene et al., 2011).  
According to Blanco et al. (2011), ǂ1-PI therapy has proven remarkable efficacy in small 
cohorts of ǂ1-PI-deficient patients who also suffer from fibromyalgia, systemic vasculitis, 
relapsing panniculitis and bronchial asthma. Although the putative benefits of ǂ1-PI therapy 
for treatment of additional rare diseases (some are listed in Table 3) requires much more 
clinical data than are currently available to support clinical efficacy and safety of ǂ1-PI 
treatment, in general it indicates a clear potential for additional ǂ1-PI supply to satisfy the 
anticipated clinical demand in near future. Because of controversy related to the additional 
clinical implications of 1-PI deficiency, more clinical data are needed to verify whether the 
reported links between 1-PI deficiency and other rare diseases are real or accidental.  
As a potent anti-inflammatory agent, 1-PI has been investigated in clinical studies for 
treatment of cystic fibrosis (Jones & Helm, 2009). Whereas patients with emphysematous 
conditions suffer from the hereditary 1-PI deficiency and, thus, insufficient levels of the 
protease inhibitor in the lungs due to impaired 1-PI synthesis in hepatocytes, patients with 
cystic fibrosis may have normal synthesis of 1-PI and suffer from severe pulmonary 
inflammation due to high excess of NE in the lungs, leading to a progressive loss of lung 
function (Allen, 1996; Siekmeier, 2010). Therefore, it has been proposed that both groups of 
patients may benefit from 1-PI augmentation therapy to prevent the deleterious effect of 
free protease (Allen, 1996; Birrer, 1995; Birrer et al, 1996) However, intravenous 
administration of 1-PI did not result in a suppression of the respiratory neutrophil elastase 
burden (McElvaney et al, 1991). Several studies have been conducted using inhalation of an 
aerosolized 1-PI in cystic fibrosis and 1-PI deficiency (Hubbard et al., 1989; Griese et al, 
2001, 2007; Martin et al, 2006; Brand et al, 2009). 
Whereas several studies that investigated the efficacy of treatment with an aerosolized 1-PI 
both in patients with cystic fibrosis and in those with 1-PI deficiency came to positive 
conclusions regarding deposition of inhaled 1-PI in the lungs and its anti-elastase activity 
(see review by Siekmeier, 2010), the conclusion from other studies was that treatment with 
1-PI did not demonstrate any clinical improvements (Martin, 2006). If further clinical 
studies support the safety and efficacy of an aerosolized1-PI, and it is approved for 
treatment of cystic fibrosis, the demand for therapeutic 1-PI preparations could be 
significantly increased.  
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Vasculitis Dowd et al., 1995; Esnault, 1997; Griffith et al., 1996 
Panniculitis 
Chowdhury et al., 2002;  Gross et al., 2009; Kjus et al., 
2002; Smith et al., 1987; Valverde et al., 2008 
Fibromyalgia Ablin et al., 2009; Blanco et al., 2004; Blanco et al., 2010 
Asthma Blanco et al., 2008; Blanco et al., 2011; Eden et al., 1997 
Pancreatitis Rabassa et al., 1995; Needlham & Stockley, 2004 
Renal  Szönyi et al., 2006; Ting et., 2008 
Diabetes Kalis et al., 2010; Lisowska-Myjak et al., 2006; 
Cancer Li et al., 2011; Lindor et al., 2010; Topic et al., 2011 
Rheumatoid arthritis Grimstein et al., 2010; Grimstein et al., 2011 
Atherosclerosis Stakisaitis et al., 2001; Talmud et al., 2003; 
Acute anterior uveitis Fearnley et al., 1988; Saari et al., 1986 
Chronic rhinosinusitis Kilty et al., 2008, 2010; Maune et al., 1995 
Table 3. Conditions other than emphysema and liver disease possibly associated with ǂ1-PI 
3.3.4 Research toward the enhancement of 1-PI-therapies 
During last decade various approaches have been considered for the enhancement of 1-PI-
based therapies. For instance, to prolong a short half-life of r-1-PI in the circulation, Cantin 
and co-workers hypothesized that conjugation of r-1-PI with polyethylene glycol (PEG) at 
Cys232 could extend the in vivo half-life of recombinant protein in blood and lung (Cantin et 
al., 2002b). According to their data, the site-specific conjugation with either 20 or 40 kD PEG at 
Cys232 of nonglycosylated r-1-PI (human) results in an active inhibitor with extended in vivo 
stability. Moreover, 72 h later after airway instillation, the PEG-r-1-PI seemed to be significantly 
better than glycosylated 1-PI at protecting the lung against elastase–induced lung hemorrhage.  
As an example of the in vitro biochemical evaluation of the concept, ǂ1−PI has been considered 
for its affinity to various small ligands and drugs for different reasons. Mainly this approach 
has been explored with respect to the peptides and small molecules in order to prevent the 
aggregation of Z mutant (e.g., Mallya et al., 2007; Chang et al. 2009). In the meantime, the 
protein’s potential for binding small ligands of pharmaceutical interest has been proposed as a 
promising approach that is directed at, and may ultimately enhance, currently existing ǂ1−PI 
therapies (Karnaukhova et al., 2010). For instance, ǂ1−PI’s affinity to retinoic acid, which is 
known for a wide range of physiological activities including alveolar repair and regrowth 
(Roche clinical studies, see Stockley, 2010; Massaro & Massaro, 1996, 1997) and tissue 
rejuvenation in various dermatologic diseases, has been convincingly demonstrated in 
biochemical experiments in vitro (Karnaukhova et al., 2010). As ǂ1−PI augmentation therapy 
cannot cure, but may only slow down, the progression of emphysema, its complexation with 
retinoic acid could be more efficient for treatment than ǂ1−PI alone. It is noteworthy that the 
interactions of ǂ1−PI with several other physiologically active ligands (including porphyrins) 
may reveal additional properties of this multifunctional serpin. 
4. Conclusions  
Since 1-PI deficiency was first described by Carl-Bertil Laurell and Sten Eriksson (Laurell & 
Eriksson, 1963) as a condition that could lead to the development of severe obstructive 
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pulmonary disease, our knowledge about 1-PI structure-function relationships and clinical 
manifestations of 1-PI deficiency has increased tremendously. Moreover, multi-disciplinary 
research efforts prompted the development of 1-PI-based augmentation therapy to 
maintain the inhibitor level above the protective threshold. Since 1987, several 1-PI 
products derived from pooled human plasma have been approved and are currently 
available to slow down the progression of emphysematous conditions in 1-PI-deficient 
patients. In addition, due to its multiple physiological activities, 1-PI has been identified for 
its putative involvement in several other rare diseases, the treatment of which may possibly 
benefit from 1-PI-based therapies. As an alternative to intravenous administration that may 
improve the efficacy of1-PI treatment, the inhalation of aerosolized 1-PI preparations has 
been in clinical trials. Recombinant versions of human 1-PI have been produced in all 
available hosts and in several transgenic animals. These efforts made a remarkable impact 
on the research realm of recombinant protein therapeutics, but did not yet bring any viable 
version of recombinant 1-PI to the treatment. In regards to therapeutic preparations and 
their use, there are several questions to be addressed when looking to the future. Keeping in 
mind the long history of replacement therapy using currently approved plasma-derived 1-
PI products, it is essential that the efficacy of 1-PI replacement therapy be clearly 
demonstrated in prospective, randomized, placebo-controlled trials. Will the efficacy of 
inhalation therapy using aerosolized 1-PI preparations be proven to be superior to that of 
the intravenous route? Will the recombinant/transgenic versions of human 1-PI be 
optimized to meet the requirements for protein therapeutics? Will other rare diseases 
currently implicated in association with 1-PI and 1-PI deficiency be clearly proven to 
benefit from 1-PI treatment? From the standpoint of product quality, safety and efficacy, 
the current state of research and development of 1-PI for therapeutic use demonstrates a 
symbiosis of the recent achievements and controversies, hopefully typical of our progress. 
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